Anlon Healthcare Ltd.
•Add ratio to table
ABOUT
AI Sector View
AI GENERATEDHealthcare
This stance relies on proxies and positioning because no direct pharma-export or healthcare operating series exists in the dataset. The depreciated currency at 95.23 (Sep/26) can support export earnings, inflation at 4.45% (Jul/26) is manageable for a defensive sector, and consumer spending remains large at INR 44743 billion (Jun/26). Strong FPI inflow of INR 10620 crore over 3 months to 2026-08-31 from INR -11381 crore in the prior 3 months adds a real sector-specific tailwind, but confidence stays capped because the fundamental drivers are indirect proxies.
PROS
- Latest quarter profit grew 397.4% YoY, showing strong momentum
- Company comfortably covers its interest (12.4x coverage)
- Company maintains a comfortable, low leverage position
CONS
- Operating cash flow has been negative in recent years
- Working capital days have increased from 299 to 426 days
* The pros and cons are machine generated based on quantitative rules.
Peer comparison
| Name | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| SUNPHARMA | 1842.00 | 36.54 | 441957.50 | 0.87 | 2901.23 | 26.53 | 15299.88 | 10.98 | 19.11 | 28.81 |
| DIVISLAB | 9326.00 | 84.64 | 247576.00 | 0.32 | 902.00 | 65.50 | 3080.00 | 27.80 | 21.51 | 40.75 |
| TORNTPHARM | 4975.00 | 86.76 | 189233.01 | 0.76 | 566.00 | 3.28 | 4921.00 | 57.32 | 19.27 | 33.81 |
| ZYDUSLIFE | 1119.50 | 24.74 | 111670.55 | 0.09 | 990.20 | -34.90 | 8017.00 | 23.97 | 21.39 | 24.54 |
| CIPLA | 1365.00 | 32.72 | 110272.68 | 0.95 | 785.55 | -39.18 | 7119.28 | 4.13 | 16.00 | 16.73 |
| LAURUSLABS | 1970.35 | 97.37 | 106460.42 | 0.10 | 362.07 | 123.94 | 2026.31 | 29.10 | 18.20 | 31.50 |
| DRREDDY | 1161.00 | 30.07 | 96906.38 | 0.69 | 435.60 | -69.10 | 8099.80 | -5.21 | 13.75 | 10.63 |
| AUROPHARMA | 1675.45 | 25.97 | 96401.69 | 0.24 | 1032.03 | 25.22 | 9150.35 | 17.44 | 12.76 | 20.54 |
| LUPIN | 2096.00 | 17.34 | 95842.92 | 0.86 | 1416.98 | 16.01 | 8276.89 | 34.28 | 28.86 | 29.59 |
| MANKIND | 2277.00 | 46.04 | 94050.37 | 0.04 | 574.09 | 29.12 | 4030.59 | 12.89 | 13.24 | 26.30 |
| GLENMARK | 2416.90 | 37.94 | 68210.88 | 0.10 | 482.83 | 927.88 | 4018.48 | 31.35 | 20.35 | 20.03 |
| AHCL | 19.52 | 36.39 | 1037.52 | 0.00 | 82.81 | — | 875.63 | 1689.56 | 21.98 | 17.81 |
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2025 | Jun 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|
| 49 | 33 | 51 | 876 | |
| 32 | 28 | 36 | 740 | |
| Operating Profit | 17 | 5 | 15 | 136 |
| OPM % | 35.13% | 14.99% | 30.05% | 15.53% |
| 0 | 0 | 0 | 1 | |
| Interest | 1 | 1 | 1 | 9 |
| Depreciation | 1 | 0 | 0 | 11 |
| Profit before Tax | 15 | 5 | 14 | 137 |
| Tax % | -7.49% | 29.12% | 23.34% | 39.37% |
| Net Profit | 0 | 4 | 11 | 83 |
| 5.15 | 0.09 | 2.33 | 0.16 |
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|
| 120 | 172 | 1,009 | |
| 88 | 124 | 835 | |
| Operating Profit | 32 | 48 | 173 |
| OPM % | 26.78% | 27.63% | 17.20% |
| 0 | 0 | 1 | |
| Interest | 4 | 4 | 12 |
| Depreciation | 2 | 2 | 12 |
| Profit before Tax | 27 | 43 | 172 |
| Tax % | 23.69% | 31.57% | 33.49% |
| Net Profit | 21 | 29 | 114 |
| EPS | 5.15 | 5.36 | — |
| Dividend Payout % | 0.00% | 0.00% | — |
COMPOUNDED SALES GROWTH
- 10 Years:
- —
- 5 Years:
- —
- 3 Years:
- —
COMPOUNDED PROFIT GROWTH
- 10 Years:
- —
- 5 Years:
- —
- 3 Years:
- —
STOCK PRICE CAGR
- 10 Years:
- —
- 5 Years:
- —
- 3 Years:
- —
- 1 Year:
- 80%
RETURN ON EQUITY
- 10 Years:
- —
- 5 Years:
- —
- 3 Years:
- —
- Last Year:
- 19%
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2025 | Mar 2026 | |
|---|---|---|
| Equity Capital | 40 | 53 |
| Minority Interest | 0 | 25 |
| 41 | 177 | |
| 67 | 44 | |
| Trade Payables | 20 | 42 |
| 15 | 33 | |
| Total Liabilities | 181 | 374 |
| 23 | 58 | |
| 1 | 1 | |
| 50 | 113 | |
| 75 | 104 | |
| Cash & Bank | 1 | 4 |
| 31 | 94 | |
| Total Assets | 181 | 374 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2025 | Mar 2026 | |
|---|---|---|
| -23 | -79 | |
| Cash from Investing | 3 | -36 |
| Cash from Financing | 19 | 119 |
| -1 | 3 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2025 | Mar 2026 | |
|---|---|---|
Documents
Corporate disclosures, annual reports, credit ratings, and concall transcripts
2026-09-07 - Anlon Healthcare Limited has informed the Exchange regarding Revised Proceedings of Annual General Meeting held on September 05, 2026
2026-09-05 - Anlon Healthcare Limited has submitted the Exchange a copy Srutinizers report of Annual General Meeting held on September 05, 2026. Further, the company has informed the Exchange regarding voting results.
2026-09-05 - Anlon Healthcare Limited has informed the Exchange regarding Proceedings of Annual General Meeting held on September 05, 2026
2026-08-25 - Anlon Healthcare Limited has informed the Exchange regarding Corrigendum to Notice of Annual General Meeting to be held on September 05, 2026
2026-08-17 - Anlon Healthcare Limited has informed the Exchange about Copy of Newspaper Publication
2026-08-14 - Anlon Healthcare Limited has informed the Exchange regarding Notice of Annual General Meeting to be held on September 05, 2026
2026-08-14 - Submission of Monitoring Agency Report for the quarter ended June 30, 2026.
2026-08-13 - Anlon Healthcare Limited has informed the Exchange that Record date for the purpose of Annual General Meeting is 28-Aug-2026.
2026-08-13 - Anlon Healthcare Limited has informed the Exchange regarding Outcome of Board Meeting held on August 13, 2026.
News
Recent coverage and analyst commentary for AHCL
Loading news…
AI Stock Analyst
Anlon Healthcare Ltd.
Sign in to Chat with AI
Log in with your 5nance account to ask institutional questions about performance, financials, and outlook.
✨ Sign In to ChatFree 5nance Account